Retinoids downregulate both p60 and p80 forms of tumor necrosis factor receptors in human histiocytic lymphoma U-937

K Totpal1, M M Chaturvedi, R LaPushin

  • 1Department of Clinical Immunology and Biological Therapy, University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

Blood
|June 15, 1995
PubMed

Insights

All-trans-retinoic acid (RA) reduces tumor necrosis factor (TNF) receptors on myeloid cells. This downregulation of TNF receptors by RA correlates with reduced anti-proliferative effects of TNF.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Retinoids are known to modulate tumor necrosis factor (TNF) effects.
  • Understanding retinoid interactions with TNF receptors is crucial for cancer research.

Purpose of the Study:

  • To investigate the effect of all-trans-retinoic acid (RA) on cell surface expression of TNF receptors.
  • To determine how RA influences TNF receptor binding, affinity, and transcript levels.

Main Methods:

  • U-937 and THP-1 cells were treated with all-trans-retinoic acid (RA).
  • 125I-labeled TNF binding assays, Scatchard analysis, and covalent cross-linking were performed.
  • Northern blot analysis and Western blotting with specific antibodies were utilized.

Main Results:

  • RA significantly decreased TNF receptor expression on U-937 and THP-1 cells in a dose- and time-dependent manner.
  • Downregulation involved decreased receptor number and reduced transcript levels, affecting both p60 and p80 TNF receptors.
  • RA treatment also decreased receptor-mediated TNF internalization and the anti-proliferative effects of TNF.

Conclusions:

  • All-trans-retinoic acid (RA) effectively downmodulates both p60 and p80 TNF receptors on myeloid cells.
  • This downregulation correlates with altered cellular responses to TNF, suggesting a role in retinoid-mediated cancer therapy.

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...